Antimicrobial resistance (AMR) poses a growing threat to global public health. This phenomenon, characterized by the ability of microorganisms to withstand the effects of antimicrobials, is primarily driven by the inappropriate use of these therapeutic agents in both human and animal health. The selective pressure exerted by antimicrobials promotes the emergence and dissemination of multidrug-resistant bacterial strains, complicating the management of infections.
The Problem with Antimicrobial Resistance
The consequences of AMR are multifaceted and severe. In addition to increasing morbidity and mortality rates, it leads to higher healthcare costs due to prolonged and complex treatments. Furthermore, AMR jeopardizes the safety of invasive medical procedures, making certain interventions riskier.
To address this major challenge, multifactorial strategies are needed. At the individual level, judicious antimicrobial prescribing is essential. At the collective level, infection prevention and control measures must be strengthened, particularly in healthcare settings. Moreover, significant efforts are being made at the research level to develop new antimicrobial molecules, improve diagnostic tools, and devise novel therapeutic strategies.
Research advancements focus on identifying new therapeutic targets, developing rapid and accurate diagnostic tests, and exploring alternative therapeutic approaches such as immunotherapy and phage therapy. However, the complexity of resistance mechanisms and the emergence of multidrug resistance represent significant challenges.
In conclusion, AMR is a global public health problem that requires a coordinated and comprehensive approach. Fundamental and clinical research plays a crucial role in combating this phenomenon, but prevention and control measures are also essential to limit the spread of resistant bacteria.
Companies that are innovating in this sector are likely to be eligible for several funding programs including government grants, and SR&ED.
